Articles Tagged With:
-
Study Suggests Need for Update in LARC Counseling About Acne
Investigators evaluated adolescent and young adult study participants seeking progestin-only long-acting reversible contraception (LARC) and found there was a risk of the contraceptive worsening acne.
-
Study: Small Decrease in Applicants to OB/GYN Residency Programs in Abortion-Ban States
Researchers looked at the impact of the overturn of Roe v. Wade on OB/GYN residency programs in the first year after the U.S. Supreme Court gave states the power to pass abortion bans with its decision in Dobbs v. Jackson Women’s Health Organization. They found there was a small but significant decrease in the number of applications to states with stricter abortion laws from 2022 to 2023.
-
What Did Supreme Court Justices Say About EMTALA and Abortion?
By the end of June, the U.S. Supreme Court will decide on whether Idaho and other states can require hospitals — through criminal laws — to turn away pregnant women experiencing a major health crisis when the best treatment for them is an abortion to end their pregnancy. Idaho presented a case that their state law preempts the Emergency Medical Treatment and Active Labor Act (EMTALA), and the federal government argued that EMTALA and the mission of protecting patients’ health and lives takes precedence.
-
EMTALA Has Protected Pregnant Patients for Three Decades — Now That Could Be at Risk
Health-preserving emergency care for pregnant women could be up to each physician’s conscience and risk-taking ability after the U.S. Supreme Court debates whether the state of Idaho is exempt from providing emergency abortion care to women who may lose their uteruses or kidneys or suffer other major health problems with delayed abortion care.
-
U.S. Supreme Court Unanimously Rejected Lawsuit Challenging FDA’s Mifepristone Decisions
Reproductive healthcare and abortion providers can exhale in relief — however briefly — because a unanimous U.S. Supreme Court decision maintains telehealth access to mifepristone, an abortion drug, in the United States.
-
Cardioversion in Obese Patients
A multicenter, single-blind, randomized clinical trial of dual vs. single defibrillator shocks for cardioverting obese patients with atrial fibrillation showed that dual defibrillation was significantly more effective without any increase in adverse events.
-
Are Women with Atrial Fibrillation Still at Higher Risk of Ischemic Stroke?
A Finnish national database study of newly diagnosed atrial fibrillation from 2007-2018 has shown that the independent association of ischemic stroke risk with female sex initially was high but trended downward to nonsignificant at the end of the study. This has implications for the risk stratification of atrial fibrillation patients regarding oral anticoagulation therapy.
-
Insights from the Apixaban vs. Aspirin for Subclinical Atrial Fibrillation Trial
An analysis of the ARTESiA trial of apixaban vs. aspirin for stroke prevention in subclinical atrial fibrillation by CHA2DS2VASc score has shown that the benefits of apixaban outweigh the risk of major bleeding at scores > 4 and the opposite is true at scores < 4.
-
Empagliflozin Post-Acute Myocardial Infarction
A prespecified further analysis of the EMPACT-MI trial has shown that patients within two weeks of an acute myocardial infarction who are at risk for heart failure who receive empagliflozin compared to placebo have significantly fewer episodes of heart failure hospitalizations over a median follow-up of 18 months.
-
Impella Scores a Big Win in Infarct-Related Cardiogenic Shock, but with Big Caveats
In this randomized controlled trial of patients presenting with ST-elevation myocardial infarction and cardiogenic shock, use of the Impella microaxial flow pump resulted in improved survival but also higher adverse safety events compared with standard care.